• Drosophila Keap1 Nuclear Condensates Under Oxidative Stress

  2026-08-14

  The reference study identifies oxidative stress–responsive nuclear condensates as a previously unrecognized organizational state of Drosophila Keap1. Domain-deletion, FRAP, and in vitro reconstitution experiments implicate the C-terminal disordered regions in condensate formation, while the Kelch domain acts as an inhibitory regulator.

• Nocodazole: From Mitotic Arrest to Translation

  2026-08-14

  Nocodazole is more than a mitotic-arrest reagent: it is a reversible microtubule perturbation tool that can help translational researchers connect spindle state, cell-cycle progression, and cap-dependent translation. This article presents a mechanism-led framework for experimental design, assay validation, and anticancer drug evaluation while defining the boundaries of what Nocodazole can and cannot establish.

• CCG-1423: RhoA Signaling at the Barrier

  2026-08-13

  CCG-1423 offers a mechanistically distinct way to interrogate RhoA transcriptional signaling, MRTF-A nuclear import, metastasis, apoptosis, and potentially virus-associated barrier remodeling. This thought-leadership guide connects the compound’s established cancer research utility with the RhoA/ROCK1/MLC2 mechanism reported in canine parvovirus infection while clearly separating evidence from translational hypothesis.

• PD 0332991 (Palbociclib HCl): Mechanism & Use

  2026-08-13

  PD 0332991, also called Palbociclib HCl, is a selective CDK4/6 inhibitor that suppresses Rb phosphorylation and promotes G1 arrest in Rb-positive research models. Product-level potency, cell-cycle, xenograft, formulation, and storage data support its use as a research tool rather than as a universal anticancer treatment.

• Nebivolol hydrochloride Research Workflows

  2026-08-12

  Build cleaner β1-adrenergic receptor experiments with a highly selective β1-adrenoceptor antagonist, while avoiding accidental interpretation as an mTOR inhibitor. This guide combines DMSO handling, receptor-signaling workflows, orthogonal yeast validation, and troubleshooting for cardiovascular pharmacology research.

• CXCR4 Theranostics in Lymphoma: Imaging to Therapy

  2026-08-12

  This 2026 review presents CXCR4 as a theranostic target in lymphoma, linking receptor biology with PET/SPECT imaging, targeted radioligand therapy, antagonists, and antibodies. Its main contribution is an integrated framework for selecting CXCR4-directed agents while recognizing physiological uptake, variable receptor expression, and compensatory CXCR7 signaling as barriers to clinical translation.

• RCN2, PPP2CA, and Cisplatin Resistance in ESCC

  2026-08-11

  The reference study identifies RCN2 as a driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance through UBR5-dependent ubiquitination and degradation of PPP2CA. Its integrated molecular, cellular, and animal experiments position the RCN2–PPP2CA–PI3K-AKT axis as a mechanistic target for future ESCC research, while also defining important questions about pathway-specific therapeutic intervention.

• Metagenomic Discovery of Potent Cas9 Inhibitors

  2026-08-11

  Forsberg and colleagues developed a phenotype-based functional metagenomic selection that uncovered ten DNA fragments encoding inhibitors of Streptococcus pyogenes Cas9. The study identified AcrIIA11 as a potent inhibitor active in bacterial and human-cell contexts, demonstrating that microbiome-derived anti-CRISPR proteins can be discovered without relying on recognizable sequence signatures.

• Pitavastatin (NK-104): In Vitro Workflow Guide

  2026-08-10

  Pitavastatin (NK-104, SKU B1124) is a high-purity HMG-CoA reductase inhibitor for controlled cell-based or biochemical studies of cholesterol biosynthesis. This guide translates the product dossier into a reproducible in vitro workflow; it should not be used as evidence for clinical use, animal dosing, or mechanism transfer across models without additional validation.

• Glucagon–GLP-1R Crosstalk Revealed by FRET

  2026-08-09

  Chepurny and colleagues used high-throughput FRET assays for cAMP, pharmacological antagonism, and molecular modeling to show that glucagon can activate the GLP-1 receptor in addition to its canonical glucagon receptor. The findings highlight receptor promiscuity as an important variable in GLP-1 receptor signaling research and in the interpretation of multi-receptor therapies for metabolic disease.

• DNase I (RNase-free) for RNA Workflows

  2026-08-08

  Improve RNA extraction, RT-PCR, and in vitro transcription sample preparation by removing DNA without introducing RNase activity. This guide also shows how controlled nuclease treatment can support RNA quality assessment in patient-derived organoid–fibroblast studies of pancreatic cancer.

• Stiripentol, LDH Inhibition, and Lactate Signaling

  2026-08-07

  Stiripentol is an LDH inhibitor that enables mechanistic study of lactate flux, astrocyte-neuron lactate shuttle modulation, and epileptiform activity. This article distinguishes direct LDH perturbation from MPC-driven lactate biology and translates recent histone lactylation findings into better assay decisions.

• Structural Determinants of ω-Agatoxin IVA Sensitivity in Cav

  2026-08-07

  The referenced study elucidates the molecular basis for the differential sensitivities of P- and Q-type Cav2.1 calcium channels to ω-agatoxin IVA, using high-resolution cryo-EM structures. These insights clarify how specific extracellular loop variations and the NP motif in the channel protein modulate toxin binding, informing targeted research on synaptic transmission and neuroprotection.

• Miltefosine: Dual Pathway Modulation for Hematological Recov

  2026-08-06

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) is a bioactive small molecule with dual action on the PI3K/Akt and Ras/MEK/ERK signaling pathways. It inhibits cancer cell proliferation and robustly promotes neutrophil differentiation, as supported by recent preclinical studies. Its validated activity profile and defined protocol parameters make it a versatile tool for hematology research.

• Morin: Mechanistic Insights and Workflow Optimization in Pod

  2026-08-06

  Explore the multifaceted bioactivity of Morin, a natural flavonoid, with an emphasis on its mechanistic inhibition of adenosine 5′-monophosphate deaminase. This article provides advanced guidance for podocyte mitochondrial assays, offering novel workflow perspectives distinct from existing resources.

16810 records 1/1121 page Next 12345 下5页 Last page